Mounjaro (tirzepatide): Uses, Pen Formulations and Safety

Mounjaro and the specific pen

Mounjaro contains tirzepatide, which acts at GIP and GLP-1 receptors. This catalogue record is the single-dose 2.5 mg/0.5 mL injection pen. Multi-dose KwikPens have a different volume per dose; the devices and their markings should not be treated as interchangeable. Tirzepatide is injected under the skin. The stated strength identifies this product, not an individual treatment recommendation.

The US label covers type 2 diabetes in adults and children aged ten years or older, and cardiovascular risk reduction in adults with type 2 diabetes at high cardiovascular risk. EU Mounjaro information also includes weight management for eligible adults. Brand indications differ between countries, so an obesity indication under one regional authorisation must not automatically be assumed for every Mounjaro pack.

Adverse effects and urgent symptoms

Nausea, diarrhoea, vomiting, constipation and abdominal discomfort are common. Severe or prolonged symptoms can cause dehydration and kidney injury. Persistent severe abdominal pain, a severe allergic reaction or symptoms suggesting gallbladder disease need medical assessment. People with serious gastric-emptying problems or diabetic eye disease require particular review. The US product is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2; whether tirzepatide causes these tumours in humans remains unknown.

Interactions and contraception

Insulin and sulfonylureas may increase hypoglycaemia risk. Tirzepatide delays stomach emptying, which can matter for orally administered medicines, particularly those needing close monitoring. Tell the anaesthesia team before general anaesthesia or deep sedation.

Contraception advice is region-specific. The US label advises users of oral hormonal contraceptives to use a non-oral method or add a barrier method for four weeks after starting tirzepatide and after each dose increase. Discuss the actual local guidance with the prescriber or pharmacist; do not assume that every GLP-1 medicine has this same interaction.

Pregnancy and breastfeeding

Tirzepatide is not recommended during pregnancy in the EU information; planned pregnancy requires advance clinical review, including the specified one-month washout. Current single-dose studies found undetectable or low milk concentrations, but infant effects and effects on milk production remain insufficiently studied. Breastfeeding decisions therefore need an individual assessment, rather than treating low measured transfer as proof of safety.

Sources

• Mounjaro — EMA EU product information — Current EU product information; sections 4.1–4.6 and patient leaflet; accessed 30 October 2026
• Mounjaro — US prescribing information — US prescribing information, revised August 2026; accessed 30 October 2026

Source check: 30 October 2026. This date records a source check, not a clinical review by a doctor or pharmacist. Personal treatment decisions require a qualified healthcare professional and the current leaflet for your own product.